WAWilly Adhimarta

Willy Adhimarta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Willy Adhimarta has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of diphenhydramine HCl on tumor necrosis factor-α levels in wistar rats with traumatic brain injury: An in vivo study

    by Venansius Ratno Kurniawan, Andi Asadul Islam, Willy Adhimarta, Andi Alfian Zainuddin, Djoko Widodo, Nasrullah, Andi Ihwan, Wahyudi, Muhammad Faruk

    Background: Traumatic brain injury (TBI) is a major cause of death and disability worldwide that imposes a significant burden on both individuals and their families. Many of the symptoms experienced by patients with TBI are thought to be mediated by the neuminflammatory process that occurs after the primary injury. Therefore, the present study aimed to determine the effect of diphenhydramine HCl (DPM) on serum levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) after TBI. Materials and methods: This was an experimental study with a pre- and post-test control group design. A total of 10 adult Wistar rats were divided into 2 groups, the DPM group and the placebo group. The effect of DPM on serum levels of TNF-alpha was evaluated at 30 min, 2 h, and 24 h after the induction of experimental TBI in the rats using Marmarou's weight-drop model. Results: TNF-alpha levels in the DPM group significantly decreased from 0 min to 24 h after TBI (p = 0.004). In the placebo group, TNF-alpha levels significantly increased from 0 min to 24 h after TBI (p < 0.001). Post hoc analysis found that TNF-alpha levels in the DPM group decreased significantly from 30 min to 2 h and from 2 h to 24 h after TBI (p = 0.019 and p = 0.005, respectively). Conclusion: The results of this study suggest that administration of DPM causes a reduction in serum levels of TNF-alpha, indicating that DPM has a significant anti-inflammatory effect in experimental rats after TBI.


  • Open Access

    Comparison of Blood Lactate Concentrations in Patients with Closed Traumatic Brain Injuries after Surgical and Conservative Interventions

    by Topan Sugara Kiaydemak, Willy Adhimarta, Nasrullah Nasrullah, Andi Ihwan, Mulawardi Mulawardi, Andi Alfian Zainuddin, Prihantono Prihantono, Djoko Widodo, Andi Asadul Islam, Muhammad Faruk

    Introduction: A major public health problem, brain injury can cause disability and death. Managing traumatic brain injury (TBI) can involve surgical interventions (e.g., evacuation and decompressive craniotomy) and/or conservative interventions without surgery (e.g., oxygenation, resuscitation, antibiotics, osmotherapy, and analgesics). Lactate, a biomarker that exerts physiological effects, is sensitive to the lack of oxygen and ischemia in organs such as the brain in both types of interventions. The aim of our study was thus to compare lactate concentrations in patients with closed brain injuries after conservative and surgical interventions. Methods: In a cohort study, lactate concentration between patients with TBI in the conservative versus surgical intervention groups were analyzed using the chi-square test, the independent t test, and Spearman’s correlation test. Results: Lactate concentrations in patients with closed brain injuries at the baseline, 24-hour, and 72-hour blood sampling time points did not significantly differ between conservative and surgical interventions (ρ > 0.05). However, reductions in lactate concentrations after 24 and 72 hours did significantly differ between the intervention groups, despite being more reduced in surgical interventions (ρ = 0.001) than in conservative ones (ρ = 0.002). Lactate concentrations were also significantly lower after 24 and 72 hours in the surgical intervention group for patients with epidural hematoma (EDH, p= 0.001) than ones without EDH (ρ < 0.001). Conclusion: Lactate concentration is a reliable prognostic predictor for assessing the severity of brain injury other than the GCS, another common clinical predictor.

  • Open Access

    Effect of erythropoietin administration on expression of mRNA brain-derived Neutrophic factor, levels of stromal cell-derived Factor-1, and neuron specific enolase in brain injury model Sprague Dawley

    by Muhammad Fadli Said, Andi Asadul Islam, Muhammad Nasrum Massi, Prihantono, Mochammad Hatta, Ilham Jaya Patellongi, Husni Cangara, Willy Adhimarta, Nasrullah, Rizha Anshori Nasution

    Background: Traumatic brain injury (TBI) is a complicated condition that is the primary cause of death and disability in children and young adults in developed countries. Various kinds of therapy have been carried out in the management of brain injury, one of which is the administration of erythropoietin (EPO). There are not many studies in Indonesia have proven that EPO administration is effective on parameters such as stromal cell-derived factor 1 (SDF-1), brain-derived neurotrophic factor (BDNF mRNA), and neuron-specific enolase (NSE) in brain injury patients. The purpose of this study was to see how EPO affected BDNF mRNA expression, SDF-1 serum levels, and NSE levels in experimental rats with TBI. Methods: This study was conducted using a rat head injury model. Fifteen rats were randomly assigned to one of three groups: A, B, or C. EPO was administered subcutis with a dose of 30.000 U/kg. Blood samples were taken after brain injury (H0), 12 h (H12), and 24 h (H24) after brain injury. Serum level of SDF-1 and NSE were measured using mRNA BDNF gene expression was measured with Real-Time-PCR, and ELISA. Results: This study found EPO increase BDNF mRNA expression in group C at H-12 (7,92 ± 0.51 vs 6.45 ± 0.33) compared to group B, and at H-24 (9.20 ± 0.56 vs 7.22 ± 0.19); increase SDF-1 levels in group C at H-12 (7,56 ± 0,54) vs 4,62 ± 0,58) compared to group B, and at H-24 (11,32 ± 4,55 vs 2,55 ± 0,70); decrease serum NSE levels in group C at H-12 (17,25 ± 2,02 vs 29,65 ± 2,33) compare to group B and at H-24 (12,14 ± 2,61 vs 37,31 ± 2,76); the values are significantly different with p < 0,05. Conclusion: EPO may have neuroprotective and anti-inflammatory properties in TBI by increasing mRNA BDNF expression and serum SDF-1 levels, and decrease serum NSE levels.


  • Open Access

    Effect of folinic acid on serum homocysteine, TNFα, IL-10, and HMGB1 gene expression in head injury model

    by Thomas Tommy, Andi A. Islam, Mochammad Hatta, Agussalim Bukhari, Nasrullah, Willy Adhimarta, Aminuddin, Andi Alfian Zainuddin

    Background: Head injury or traumatic brain injury is the leading cause of mortality and morbidity. Many modalities of neuroprotection had been developed in brain injury but there was no much information regarding folinic acid's effect on neuroinflammation associated with homocysteine, TNFα, IL-10, and HMGB1. Objective: This study aimed to investigate whether folinic acid has improving effect on head injury model. Method: This study was done in the rat's head injury model using modified Marmarou weight drop model. Fifteen rats were randomized and grouped into 3 groups: Group A: Folinic acid (+), head injury (−); Group B: Folinic acid (−), head injury (+); Group C: Folinic acid (+), head injury (+). Folinic acid was administered intraperitoneally with a dose of 60 mg/m2. Blood samples were taken immediately after head injury (H0), 12 h (H12), and 24 h (H24) after head injury from the lateral vein of tail. Serum level of homocysteine, TNFα, and IL-10 were measured using ELISA, and HMGB1 gene expression was measured with Real-Time RT-PCR. Results: This study found serum level of homocysteine, TNFα, IL-10 and HMGB1 gene expression were markedly increased at all time points after head injury. Significantly lower level of serum homocysteine, TNFα, IL-10 and HMGB1 gene expression were found after 24 h treatment with folinic acid in group C compared to those in group B. Conclusion: Folinic acid may have anti-inflammatory properties in traumatic brain injury by inhibition of serum level of homocysteine, TNFα, IL-10 and HMGB1 gene expression.